Lifeboat Foundation

Nanobots, tiny nano-sized robots and vehicles that can navigate through blood vessels to reach the site of a disease could be used to deliver drugs to tumours that are otherwise difficult to treat.

Once injected or swallowed, most drugs rely upon the movement of body fluids to find their way around the body. It means that some types of disease can be difficult to treat effectively in this way.

One aggressive type of brain tumour known as glioblastoma, for example, kills hundreds of thousands of people a year. But because it produces finger-like projections into a patient’s brain tissue that damage the blood vessels around them, it is hard for drugs to reach the tumour site.

Hello everybody! In this episode, we interview Felix Werth, a trully hero of the rejuvenation field: in 2015 he created a party in Germany to defend more investments in our field, and his party is contesting the general elections in the country on September 26th 2021! However, he needs our help right now, since his party has until July 19th to collect enough signatures to participate in 14 German states covering 98% of the country’s population. So be sure to check the interview and the party’s website (https://parteifuergesundheitsforschung.de) to see how you can help.

In this episode of ImmortaliCast, Nicolas and Nina talk to Felix Werth, the founder and leader of the German Party for Health Research, a party with a single issue: 10% of the government budget should be spent on research for the development of treatments of age-related diseases. The party will contest the German general elections of September 26th 2021.

Continue reading “Felix Werth: The rejuvenation field in the ballot in Germany” »

This product came out months ago with some shocking numbers as to effect. But those effects were in mice tests. 10–20% increase in lifespan and 55% increase in healthspan. It is AKG, Rejuvant, it’s a product you can buy now. There will be a part 2 of this interview so I hope to hear about human data.

Here we present an interview with Tom Weldon the founder and CEO of Ponce de Leon Health, which makes Rejuvant a Calcium AKG based supplement. In this video Tom talks through the process and reasons for selecting CaAKG. He also talks about some of the other results that they found in their tests, especially with respect to mixing different supplements and their combined effects.

Continue reading “CaAKG — The Science Behind Rejuvant | Tom Weldon Interview Series Part I” »

There are Sirt6 activators on the market, but since we are not seeing any major news about results I would question their value.

SPONSOR: Longevity. Technology — https://www.longevity.technology/?utm_source=SSS&utm_medium=…aign=Sirt6

Continue reading “The longevity sirtuin – what you need to know about SIRT6” »

CHICAGO, IL — Scientists are already preparing for a possible next coronavirus pandemic to strike, keeping with the seven-year pattern since 2004.

In future-looking research, Northwestern University Feinberg School of Medicine scientists have identified a novel target for a drug to treat SARS-CoV-2 that also could impact a new emerging coronavirus.

“God forbid we need this, but we will be ready,” said Karla Satchell, professor of microbiology-immunology at Feinberg, who leads an international team of scientists to analyze the important structures of the virus. The Northwestern team previously mapped the structure of a virus protein called nsp16, which is present in all coronaviruses. This new study provides critical information that could aid drug development against future coronaviruses as well as SARS-CoV-2.

The population on Earth is increasingly growing and people are expected to live longer in the future. Thus, better and more reliable therapies to treat human diseases such as Alzheimer’s and cardiovascular diseases are crucial. To cope with the challenge of ensuring healthy aging, a group of international scientists investigated the potential of biosynthesising several polyamines and polyamines analogs with already known functionalities in treating and preventing age-related diseases.

One of the most interesting molecules to study was spermidine, which is a natural product already present in people’s blood and an inducer of autophagy that is an essential cellular process for clearing damaged proteins, e.g., misfolded proteins in brain cells that can cause Alzheimer’s. When people get older the level of spermidine in the blood decrease and dietary supplements, or certain food products are needed to maintain a stable and high level of spermidine in the blood. However, those products are difficult to produce with traditional chemistry due to their structural complexity and extraction of natural resources is neither a commercially viable nor a sustainable approach.

Therefore, the researchers instead decided to open their biochemical toolbox and use classical metabolic engineering strategies to engineer the yeast metabolism to produce polyamines and polyamines analogs.

Research conducted by Qiang et al has discovered a link between a protein in red blood cells and age-related decline in cognitive performance. Published in the open access journal PLOS Biology on 17th June 2021, the study shows that depleting mouse blood of the protein ADORA2B leads to faster declines in memory, delays in auditory processing, and increased inflammation in the brain.

As life expectancies around the world increase, so are the number of people who will experience age-related cognitive decline. Because the amount of oxygen in the blood also declines with age, the team hypothesized that aging in the brain might be naturally held at bay by adenosine receptor A2B (ADORA2B), a protein on the membrane of red blood cells which is known to help release oxygen from the blood cells so it can be used by the body. To test this idea, they created mice that lacked ADORA2B in their blood and compared behavioral and physiological measures with control mice.

The team found that as the mice got older, the hallmarks of cognitive decline—poor memory, hearing deficits, and inflammatory responses in the brain—were all greater in the mice lacking ADORA2B than in the control mice. Additionally, after experiencing a period of oxygen deprivation, the behavioral and physiological effects on young mice without ADORA2B were much greater than those on normal young mice.

More than a year later, scientists finally figured out what caused this famous star to dim.

More than a year after Betelgeuse’s great dimming event, scientists have finally figured out what happened to cause this star to lose its brightness.

This looks extremely promising:

SAN DIEGO, June 17, 2021 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced results from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK0214, a novel, orally available small molecule thyroid receptor beta (TRβ) agonist in development for the potential treatment for X-linked adrenoleukodystrophy (X-ALD). In this study, VK0214 demonstrated encouraging safety and tolerability, as well as a predictable pharmacokinetic (PK) profile. The company expects to initiate a Phase 1b study of VK0214 in patients with X-ALD in the coming weeks.

The Phase 1 trial was a randomized, double-blind, placebo-controlled study in healthy volunteers. The primary objective of the study was to evaluate the safety and tolerability of VK0214 administered orally for up to 14 days. The secondary objective was to evaluate the pharmacokinetics of VK0214 following single and multiple oral doses. The first portion of the study evaluated single doses of VK0214; in the second portion of the study subjects received VK0214 once daily for 14 days. Subsequent cohorts in both parts of the study received successively higher VK0214 doses.

VK0214 was shown to be safe and well-tolerated at all doses evaluated in this study. No serious adverse events were reported, and no treatment or dose-related trends were observed for vital signs, gastrointestinal effects, cardiovascular measures, or physical examinations. VK0214 demonstrated dose-dependent exposures, no evidence of accumulation following multiple doses, and a half-life consistent with anticipated once-daily dosing regimens.

Continue reading “Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214” »